Video

Dr. Borchmann on Next Steps With Tisagenlecleucel in DLBCL

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma.

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma (DLBCL).

In findings from the phase II JULIET study, the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel showed an objective response rate of 52% in adult patients with relapsed/refractory DLBCL. Following these encouraging results, Borchmann says that physicians would like to see tisagenlecleucel moved to earlier lines of therapy.

This is a very difficult-to-treat patient population, Borchmann says, and outcomes for second-line treatment for patients are very poor, regardless of transplant eligibility status. A randomized phase III trial has been planned to compare tisagenlecleucel to second-line standard of care. This trial will be very important, Borchmann says, because efficacy for high-dose chemotherapy and transplantation is low, and toxicities are high.

Related Videos
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Marc Machaalani, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD